Daniel Cantillon
Cardiovascular Disease · Cleveland, OHNPI 1508030024
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Abbott at 47.6% of the total. Reporting peaked in 2022 at $60,651 and has fallen 100.0% since, to $23 in 2024. Among cardiovascular disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $610.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$67K
- Boston Scientific$52K
- Masimo Corporation$19K
- Stryker$2K
- Biosense Webster, Inc.$899
- Impulse Dynamics (USA) Inc.$48
Across 153 payments — averaging $7433.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$912K
- Boston Scientific$225K
What the payments were for
- Consulting fees$77,36555%
- Speaking & faculty fees$29,65021%
- Travel & lodging$29,19121%
- Food & beverage$4,1593%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 120 | $66,823 |
| Boston Scientific | 77 | $51,707 |
| Masimo Corporation | 24 | $18,766 |
| Stryker | 6 | $2,123 |
| Biosense Webster, Inc. | 2 | $899 |
| Impulse Dynamics (USA) Inc. | 1 | $48 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CLINICAL TRIAL PRODUCT$24,812
- GENERAL - THERAPIES$13,702
- Ensite Cardiac Mapping System$12,404
- SedLine$10,140
- AVEIR$8,638
- ENSITE PRECISION$7,075
- HeartMate$5,796
- ACCENT$4,675
- GENERAL BRADY$4,438
- Nanostim Leadleas Pacemaker$4,399
- VIEWMATE$3,738
- SET and rainbow SET$3,296
- Carto 3$2,800
- GENERAL PAIN MANAGEMENT$2,796
- S-ICD System Magnet$2,624
- EnSite Precision Cardiac Mapping System$2,200
- HeartMate PHP$2,100
- Patient SafetyNet System$2,000
- REPROCESSED EP CATHETERS$1,750
- Merlin Connectivity and Remote$1,375
How this compares
$140,365 in reported general payments places this provider in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Cleveland
- Guilherme AttizzaniCleveland$1.3M
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Mazen HannaCleveland$208K
- Brian HoitCleveland$207K
- Steven NissenCleveland$149K
- Serge HarbCleveland$134K
- Wael JaberCleveland$124K
- Milind DesaiCleveland$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.